June 18 (Reuters) - The U.S. Food and Drug Administration is investigating the cases of two individuals who died after injections with Eli Lilly and Co.'s long-acting treatment for schizophrenia, Zyprexa Relprevv.
Both patients died three to four days after receiving "an appropriate dose" of the medicine, and both had very high levels of the drug in their bloodstreams, the FDA said in a bulletin released on its website on Tuesday.
The medicine's package insert carries a prominent "black box" warning of risk from post-injection delirium sedation syndrome, or PDSS, a serious condition in which the drug enters the blood too quickly following an injection, causing greatly elevated levels of the drug in the bloodstream. High doses of the drug can cause delirium, cardiopulmonary arrest, heart rhythm problems, sedation and coma, the FDA said.
Lilly said it was not clear whether the two deaths were related to use of the drug.
"We are continuing to evaluate this important safety issue and will communicate any clinically significant safety information that affects the product," Lilly spokesman Morry Smulevitz said in an emailed statement.
About 45,000 people have taken the drug worldwide since the FDA approved it in late 2009.
In Lilly's clinical trials of Zyprexa Relprevv, cases of PDSS were seen within three hours of taking the drug, but no deaths from the syndrome were seen, the FDA said.
Zyprexa Relprevv comes with warnings that patients must stay at the doctor's office for at least three hours after it is given so they can be monitored.
The drug is a long-acting version of Lilly's widely used oral Zyprexa treatment, which was the company's biggest product until it began facing competition from cheaper generics in 2011.
Zyprexa Relprevv competes with other long-acting treatments such as Johnson & Johnson's Invega Sustenna. It is meant to offer weeks of symptom control for schizophrenia patients, who often fail to take their medication regularly.
Lilly's Smulevitz said 82 previous deaths of patients who took the drug had been reported since the drug was introduced, but that Lilly could determine no "pattern, trend or causal connection" between the deaths and use of the drug. Tuesday's FDA safety alert was the first issued by the FDA on the product, he said.
Asked why the agency had highlighted the two most recent deaths, FDA spokeswoman Sandy Walsh said, "These deaths are unique because we have postmortem blood levels (of the drug) that were very high and the cause of death was not clear." She said the FDA's investigation is continuing.
Dr. Dolores Malaspina, professor of psychiatry at New York University School of Medicine, said the unresolved safety issue was of concern, but not likely to decrease demand for Zyprexa Relprevv or similar medicines.
"These drugs are absolutely necessary, but we need to constantly think of the risks and benefits to make sure people with mental illness get adequate medical care, not just psychiatric care," Malaspina said.
She noted that people with schizophrenia and other severe mental illnesses, on average, have life spans many years lower than the general population, especially because of heart disease and metabolic diseases like diabetes.
Lilly said Zyprexa Relprevv's global sales were "less than $60 million" in 2012. The company has annual sales of more than $20 billion.
Global sales of Lilly's Zyprexa franchise plunged 49 percent to $284 million in the first quarter of 2013 as cheaper generic forms of the oral treatment continued to gain market share.
Lilly shares were little changed Tuesday on the New York Stock Exchange.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.